TY - JOUR
T1 - A review on the current status and definitions of activity indices in inflammatory bowel disease
T2 - how to use indices for precise evaluation
AU - Kishi, Masahiro
AU - Hirai, Fumihito
AU - Takatsu, Noritaka
AU - Hisabe, Takashi
AU - Takada, Yasumichi
AU - Beppu, Tsuyoshi
AU - Takeuchi, Ken
AU - Naganuma, Makoto
AU - Ohtsuka, Kazuo
AU - Watanabe, Kenji
AU - Matsumoto, Takayuki
AU - Esaki, Motohiro
AU - Koganei, Kazutaka
AU - Sugita, Akira
AU - Hata, Keisuke
AU - Futami, Kitarou
AU - Ajioka, Yoichi
AU - Tanabe, Hiroshi
AU - Iwashita, Akinori
AU - Shimizu, Hirotaka
AU - Arai, Katsuhiro
AU - Suzuki, Yasuo
AU - Hisamatsu, Tadakazu
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - Many clinical trials have been conducted for inflammatory bowel disease (IBD), so various clinical indices (CIs) and endoscopic indices (EIs) have also been evaluated. However, recently, with the progress of IBD management, review of established indices from previous studies, and establishment of new indices, the landscape of the use of indices in clinical trials have changed. We investigated the number and frequency of the indices adapted in recent clinical trials for ulcerative colitis (CI and EI) and Crohn’s disease (CI, EI, index related to magnetic resonance imaging, index for evaluating patient-reported outcomes, and health-related quality of life). Based on the results, we selected representative indices and further reviewed their content and characteristics. Moreover, various definitions, including clinical and endoscopic response or remission, have been described by means of representative indices in clinical trials.
AB - Many clinical trials have been conducted for inflammatory bowel disease (IBD), so various clinical indices (CIs) and endoscopic indices (EIs) have also been evaluated. However, recently, with the progress of IBD management, review of established indices from previous studies, and establishment of new indices, the landscape of the use of indices in clinical trials have changed. We investigated the number and frequency of the indices adapted in recent clinical trials for ulcerative colitis (CI and EI) and Crohn’s disease (CI, EI, index related to magnetic resonance imaging, index for evaluating patient-reported outcomes, and health-related quality of life). Based on the results, we selected representative indices and further reviewed their content and characteristics. Moreover, various definitions, including clinical and endoscopic response or remission, have been described by means of representative indices in clinical trials.
KW - Clinical index
KW - Crohn’s disease
KW - Endoscopic index
KW - Inflammatory bowel disease
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85125496907&partnerID=8YFLogxK
U2 - 10.1007/s00535-022-01862-y
DO - 10.1007/s00535-022-01862-y
M3 - 総説
C2 - 35235037
AN - SCOPUS:85125496907
SN - 0944-1174
VL - 57
SP - 246
EP - 266
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 4
ER -